Skip to main content
Top
Published in: Journal of Nephrology 4/2015

01-08-2015 | Original Article

Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells

Authors: Gianluigi Zaza, Valentina Masola, Simona Granata, Gloria Bellin, Alessandra Dalla Gassa, Maurizio Onisto, Giovanni Gambaro, Antonio Lupo

Published in: Journal of Nephrology | Issue 4/2015

Login to get access

Abstract

Background

Prolonged cold ischemia time, the period from the start of perfusion with cold preservation fluid after cessation of circulation due to arterial clamping until transplantation in the recipient, could induce epithelial-to-mesenchymal transition (EMT) in renal tubular cells, a process associated with chronic graft damage. In this context, everolimus (EVE) and sulodexide (SUL) could potentially slow down this process.

Methods

To assess whether SUL (50 μg/ml), EVE (at 5, 10, 100 nM) or their combination were able to inhibit EMT in human renal epithelial proximal tubular cells (HK-2) reoxygenated after 24 h under hypoxic conditions, we used classical biomolecular strategies.

Results

Hypoxia induced upregulation of alpha smooth muscle actin (α-SMA), fibronectin (FN) and vimentin at gene-expression and α-SMA and FN at protein levels. However, the addition, after reoxygenation, of SUL plus low-dose EVE (5 nM) to the cell culture reversed this condition. Moreover, SUL and EVE were able to inhibit the hypoxia-induced Akt phosphorylation in HK2 cells and their morphological changes. Similarly, SUL was able to reverse the hyper-expression of EMT markers induced by high EVE dosage (100 nM) in cells cultured under both normoxic and hypoxic conditions.

Conclusions

Our data reveal, for the first time, that sulodexide, alone or combined to low doses of everolimus, may hinder EMT in renal cells following hypoxia or minimize fibrotic complications due to high dosage of mammalian target of rapamycin inhibitors.
Literature
1.
go back to reference Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T (2012) New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 8(6):339–347PubMedCrossRef Bon D, Chatauret N, Giraud S, Thuillier R, Favreau F, Hauet T (2012) New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 8(6):339–347PubMedCrossRef
2.
go back to reference Kwiatkowski A, Wszoła M, Kosieradzki M, Danielewicz R, Ostrowski K, Domagala P, Lisik W, Fesołowicz S, Michalak G, Trzebicki J, Durlik M, Paczek L, Rowiński W, Chmura A (2009) The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 14:14–17PubMed Kwiatkowski A, Wszoła M, Kosieradzki M, Danielewicz R, Ostrowski K, Domagala P, Lisik W, Fesołowicz S, Michalak G, Trzebicki J, Durlik M, Paczek L, Rowiński W, Chmura A (2009) The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 14:14–17PubMed
3.
go back to reference Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study Group (2012) Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 366(8):770–771PubMedCrossRef Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study Group (2012) Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 366(8):770–771PubMedCrossRef
4.
go back to reference Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML (2006) Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 6:1111–1131PubMedCrossRef Meier-Kriesche HU, Li S, Gruessner RW, Fung JJ, Bustami RT, Barr ML (2006) Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant 6:1111–1131PubMedCrossRef
5.
go back to reference Meier-Kriesche HU, Schold JD, Srinivas TR, Kapplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378–383PubMedCrossRef Meier-Kriesche HU, Schold JD, Srinivas TR, Kapplan B (2004) Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4:378–383PubMedCrossRef
6.
go back to reference US Renal Data System, USRDS (2013) Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013 US Renal Data System, USRDS (2013) Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013
7.
go back to reference Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82:603–611PubMedCrossRef Ojo AO (2006) Cardiovascular complications after renal transplantation and their prevention. Transplantation 82:603–611PubMedCrossRef
8.
go back to reference Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333PubMedCrossRef Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR (2003) The natural history of chronic allograft nephropathy. N Engl J Med 349:2326–2333PubMedCrossRef
9.
go back to reference Chapman JR, O’Connell PJ, Nankivell BJ (2005) Chronic renal allograft dysfunction. J Am Soc Nephrol 16(10):3015–3026PubMedCrossRef Chapman JR, O’Connell PJ, Nankivell BJ (2005) Chronic renal allograft dysfunction. J Am Soc Nephrol 16(10):3015–3026PubMedCrossRef
12.
go back to reference Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347:103–116PubMedCrossRef Carew RM, Wang B, Kantharidis P (2012) The role of EMT in renal fibrosis. Cell Tissue Res 347:103–116PubMedCrossRef
13.
go back to reference Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF (2005) Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5:1367–1374PubMedCrossRef Vongwiwatana A, Tasanarong A, Rayner DC, Melk A, Halloran PF (2005) Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5:1367–1374PubMedCrossRef
14.
go back to reference Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois YC (2006) Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6:2937–2946PubMedCrossRef Hertig A, Verine J, Mougenot B, Jouanneau C, Ouali N, Sebe P, Glotz D, Ancel PY, Rondeau E, Xu-Dubois YC (2006) Risk factors for early epithelial to mesenchymal transition in renal grafts. Am J Transplant 6:2937–2946PubMedCrossRef
15.
16.
go back to reference Hernández D, Estupiñán S, Pérez G, Rufino M, González-Posada JM, Luis D, Delgado P, Rodríguez A, Marrero D, Porrini E, Torres A (2008) Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transplant Int 21(10):955–962CrossRef Hernández D, Estupiñán S, Pérez G, Rufino M, González-Posada JM, Luis D, Delgado P, Rodríguez A, Marrero D, Porrini E, Torres A (2008) Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transplant Int 21(10):955–962CrossRef
17.
go back to reference Salahudeen AK, Haider N, May W (2004) Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 65(2):713–718PubMedCrossRef Salahudeen AK, Haider N, May W (2004) Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 65(2):713–718PubMedCrossRef
18.
19.
go back to reference Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85:125–134PubMedCrossRef Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85:125–134PubMedCrossRef
20.
go back to reference Geissler EK, Schlitt HJ (2010) The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 78(11):1075–1079PubMedCrossRef Geissler EK, Schlitt HJ (2010) The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation. Kidney Int 78(11):1075–1079PubMedCrossRef
21.
go back to reference Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 7(3):e33626PubMedCentralPubMedCrossRef Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 7(3):e33626PubMedCentralPubMedCrossRef
22.
go back to reference Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213PubMedCentralPubMedCrossRef Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213PubMedCentralPubMedCrossRef
23.
go back to reference Masola V, Zaza G, Gambaro G (2014) Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i74–i79PubMedCrossRef Masola V, Zaza G, Gambaro G (2014) Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1):i74–i79PubMedCrossRef
24.
go back to reference Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11:292PubMedCentralPubMedCrossRef Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11:292PubMedCentralPubMedCrossRef
25.
go back to reference Kosieradzki M, Rowiński W (2008) Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 40(10):3279–3288PubMedCrossRef Kosieradzki M, Rowiński W (2008) Ischemia/reperfusion injury in kidney transplantation: mechanisms and prevention. Transplant Proc 40(10):3279–3288PubMedCrossRef
26.
go back to reference van der Vliet JA, Warlé MC (2013) The need to reduce cold ischemia time in kidney transplantation. Curr Opin Organ Transplant 18(2):174–178PubMedCrossRef van der Vliet JA, Warlé MC (2013) The need to reduce cold ischemia time in kidney transplantation. Curr Opin Organ Transplant 18(2):174–178PubMedCrossRef
27.
go back to reference Ponticelli C (2014) Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 29(6):1134–1140PubMedCrossRef Ponticelli C (2014) Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 29(6):1134–1140PubMedCrossRef
28.
go back to reference Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503–1520PubMedCrossRef Devarajan P (2006) Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 17(6):1503–1520PubMedCrossRef
29.
go back to reference Perico N, Cattaneo D, Sayegh MH, Remuzzi G (2004) Delayed graft function in kidney transplantation. Lancet 364(9447):1814–1827PubMedCrossRef Perico N, Cattaneo D, Sayegh MH, Remuzzi G (2004) Delayed graft function in kidney transplantation. Lancet 364(9447):1814–1827PubMedCrossRef
30.
go back to reference Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M (2004) Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65:871–880PubMedCrossRef Manotham K, Tanaka T, Matsumoto M, Ohse T, Inagi R, Miyata T, Kurokawa K, Fujita T, Ingelfinger JR, Nangaku M (2004) Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int 65:871–880PubMedCrossRef
31.
go back to reference Gottmann U, Mueller-Falcke A, Schnuelle P, Birck R, Nickeleit V, van der Woude FJ, Yard BA, Braun C (2007) Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys. Transpl Int 20(6):542–549PubMedCrossRef Gottmann U, Mueller-Falcke A, Schnuelle P, Birck R, Nickeleit V, van der Woude FJ, Yard BA, Braun C (2007) Influence of hypersulfated and low molecular weight heparins on ischemia/reperfusion: injury and allograft rejection in rat kidneys. Transpl Int 20(6):542–549PubMedCrossRef
32.
go back to reference Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G, Ankarali H (2012) Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg 7:123PubMedCentralPubMedCrossRef Gedik HS, Korkmaz K, Erdem H, Karakilic E, Lafci G, Ankarali H (2012) Protective effect of heparin in the end organ ischemia/reperfusion injury of the lungs and heart. J Cardiothorac Surg 7:123PubMedCentralPubMedCrossRef
33.
go back to reference Zhou T, Chen JL, Song W, Wang F, Zhang MJ, Ni PH, Geng JG (2002) Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats. World J Gastroenterol 8(5):897–900PubMed Zhou T, Chen JL, Song W, Wang F, Zhang MJ, Ni PH, Geng JG (2002) Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats. World J Gastroenterol 8(5):897–900PubMed
34.
go back to reference Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group, Sirolimus CONVERT Trial Study Group (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233PubMedCrossRef Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group, Sirolimus CONVERT Trial Study Group (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233PubMedCrossRef
35.
go back to reference Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K (2008) Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 22:366PubMedCrossRef Holdaas H, Bentdal Ø, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K (2008) Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 22:366PubMedCrossRef
36.
go back to reference Budde K, Becker T, Sommerer C et al (2009) Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 9:259 (Abstract 237) Budde K, Becker T, Sommerer C et al (2009) Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the Zeus study. Am J Transplant 9:259 (Abstract 237)
37.
go back to reference Weir M, Mulgaonkar S, Pearson T et al (2009) Mycophenolatemofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 9:200 (Abstract 33) Weir M, Mulgaonkar S, Pearson T et al (2009) Mycophenolatemofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 9:200 (Abstract 33)
38.
go back to reference Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115PubMedCrossRef Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, Moulin B, Frouget T, Le Meur Y, Glotz D, Heng AE, Onno C, Buchler M, Girardot-Seguin S, Hurault de Ligny B (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115PubMedCrossRef
39.
go back to reference Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837–847PubMedCrossRef Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, Kramer S, Fischer W, Gschaidmeier H, Pietruck F, ZEUS Study Investigators (2011) Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377(9768):837–847PubMedCrossRef
40.
go back to reference Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320–1328PubMedCrossRef Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320–1328PubMedCrossRef
41.
go back to reference Pallet N, Legendre C (2013) Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 12(2):177–186PubMedCrossRef Pallet N, Legendre C (2013) Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 12(2):177–186PubMedCrossRef
42.
go back to reference Lieberthal W, Fuhro R, Andry CC (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693–F706PubMed Lieberthal W, Fuhro R, Andry CC (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693–F706PubMed
43.
go back to reference Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC (2009) Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 22:681–687PubMedCrossRef Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC (2009) Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 22:681–687PubMedCrossRef
44.
go back to reference Dantal J, Berthoux F, Moal MC (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-months results of a randomized, multicenter trial. Transpl Int 23(11):1084–1093PubMedCrossRef Dantal J, Berthoux F, Moal MC (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-months results of a randomized, multicenter trial. Transpl Int 23(11):1084–1093PubMedCrossRef
45.
go back to reference Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280PubMedCentralPubMedCrossRef Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280PubMedCentralPubMedCrossRef
46.
go back to reference Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A (2014) mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 5:495CrossRef Zaza G, Granata S, Tomei P, Masola V, Gambaro G, Lupo A (2014) mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 5:495CrossRef
47.
go back to reference Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8(4):742–753PubMedCentralPubMedCrossRef Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8(4):742–753PubMedCentralPubMedCrossRef
48.
go back to reference Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940PubMedCrossRef Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940PubMedCrossRef
50.
go back to reference Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856–5864PubMedCrossRef Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856–5864PubMedCrossRef
51.
go back to reference Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658–2664PubMed Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658–2664PubMed
Metadata
Title
Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells
Authors
Gianluigi Zaza
Valentina Masola
Simona Granata
Gloria Bellin
Alessandra Dalla Gassa
Maurizio Onisto
Giovanni Gambaro
Antonio Lupo
Publication date
01-08-2015
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 4/2015
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-015-0216-y

Other articles of this Issue 4/2015

Journal of Nephrology 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine